🦴 NSAID vs Muscle Relaxant Back Pain Simulator

Acute Back Pain: Inflammation Meets Spasm

Acute back pain usually mixes tissue inflammation and muscle spasm.

• 80%: Lifetime prevalence (affects most adults)
• 6 weeks: Typical resolution (for most cases)
• ~60%: Inflammatory component (of presentations)
• ~70%: Spasm component (of presentations)

Two overlapping mechanisms

Damaged tissue inflames while nearby muscles spasm protectively.

Why it hurts

Prostaglandins sensitize nerves; tight fibers restrict local blood flow.

Diagnosis challenge

Exam findings rarely separate inflammatory pain from spasm pain.

Most patients have some of both, not purely one cause.

NSAIDs: Blocking COX to Cool Inflammation

NSAIDs inhibit COX enzymes, cutting prostaglandin output at the injury.

• COX-1/2: Target enzyme (cyclooxygenase family)
• 30–60 min: Onset of relief (oral dosing)
• up to 80%: Prostaglandin drop (at full dose)
• minimal: Spasm effect (not a direct target)

COX inhibition

NSAIDs block COX-1 and COX-2 from making prostaglandins.

Local anti-inflammatory action

Less prostaglandin means less swelling, heat, and nerve sensitization.

Limits

NSAIDs barely touch pure muscle spasm or hypertonicity.

Best when inflamed tissue, not spasm, drives the pain.

Muscle Relaxants: Calming Spasm Centrally

Muscle relaxants act on the central nervous system to ease spasm.

• CNS: Site of action (brainstem / spinal cord)
• ~1 hour: Onset of relief (oral dosing)
• up to 75%: Spasm reduction (at full dose)
• none: Inflammation effect (not anti-inflammatory)

Central action

Relaxants dampen motor neuron signaling that sustains spasm.

Loosening tight fibers

Reduced firing lets coiled muscle fibers unwind and relax.

Limits

Relaxants do nothing for prostaglandin-driven tissue inflammation.

Best when tight, guarding muscle, not inflammation, dominates.

Comparing and Combining Both Mechanisms

Together, NSAIDs and relaxants target different halves of the pain.

• Inflammation: NSAID targets (peripheral tissue)
• Spasm: Relaxant targets (central nervous system)
• modest gain: Combined therapy trials (over either alone)
• low: Side effect overlap (different pathways)

Complementary targets

One drug cools tissue, the other calms muscle tone.

Evidence on combining

Combination trials show only modest added benefit overall.

Practical trade-off

More drugs mean more side effects for modest extra relief.

Matching the drug to the dominant symptom often works best.

Choosing Therapy by Dominant Symptom

Treatment choice should follow whether inflammation or spasm dominates.

• NSAID first: Inflammation-dominant (reduce tissue swelling)
• Relaxant first: Spasm-dominant (reduce muscle guarding)
• consider both: Mixed presentation (short course)
• NSAID first-line: Guideline stance (relaxants adjunct only)

Reading the presentation

Palpable tight bands suggest spasm; localized swelling suggests inflammation.

Stepwise approach

Start with NSAIDs, add a relaxant only if spasm persists.

Individualizing care

Sedation risk from relaxants favors short, targeted courses.

Symptom-matched therapy beats reflexively prescribing both drugs.